Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$8.05|
|52 Week High||US$2.96|
|52 Week Low||US$9.15|
|1 Month Change||64.96%|
|3 Month Change||67.71%|
|1 Year Change||130.66%|
|3 Year Change||-51.48%|
|5 Year Change||-41.41%|
|Change since IPO||-42.54%|
Recent News & Updates
Is Adamas Pharmaceuticals (NASDAQ:ADMS) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Adamas Pharmaceuticals: Share Price Range-Bound Despite Steady Revenue Growth
Adamas Pharmaceuticals reported their Q1 earnings with a slight beat on EPS and a slight miss on revenue. GOCOVRI continues to report impressive growth despite a lackluster launch. Despite the commercial progress, the ADMS share price remains suppressed. It looks as if the Street is waiting to see if and when the company will clear a profit. I reloaded on top of my core position in hopes Adamas will break even around 2024, but I willing to unload due to the ticker being in purgatory.
|ADMS||US Biotechs||US Market|
Return vs Industry: ADMS exceeded the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: ADMS exceeded the US Market which returned 30.3% over the past year.
Stable Share Price: ADMS is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 22% a week.
Volatility Over Time: ADMS's weekly volatility has increased from 14% to 22% over the past year.
About the Company
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy.
Adamas Pharmaceuticals Fundamentals Summary
|ADMS fundamental statistics|
Is ADMS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ADMS income statement (TTM)|
|Cost of Revenue||US$2.00m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.20|
|Net Profit Margin||-66.82%|
How did ADMS perform over the long term?See historical performance and comparison
Is Adamas Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ADMS ($8.05) is trading below our estimate of fair value ($47.55)
Significantly Below Fair Value: ADMS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ADMS is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ADMS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ADMS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ADMS has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.
How is Adamas Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ADMS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: ADMS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ADMS's is expected to become profitable in the next 3 years.
Revenue vs Market: ADMS's revenue (15.2% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: ADMS's revenue (15.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ADMS's Return on Equity is forecast to be high in 3 years time
How has Adamas Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ADMS is currently unprofitable.
Growing Profit Margin: ADMS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ADMS is unprofitable, and losses have increased over the past 5 years at a rate of 0.9% per year.
Accelerating Growth: Unable to compare ADMS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ADMS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: ADMS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Adamas Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: ADMS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: ADMS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: ADMS has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: ADMS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ADMS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ADMS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Adamas Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ADMS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ADMS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ADMS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ADMS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ADMS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Neil McFarlane (48 yo)
Mr. Neil F. Mcfarlane serves as Chief Executive Officer and Director of Adamas Pharmaceuticals, Inc. since September 16, 2019. Mr. Mcfarlane served as Chief Operating Officer of Retrophin, Inc. since Augus...
CEO Compensation Analysis
Compensation vs Market: Neil's total compensation ($USD1.69M) is about average for companies of similar size in the US market ($USD1.69M).
Compensation vs Earnings: Neil's compensation has been consistent with company performance over the past year.
Experienced Management: ADMS's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Experienced Board: ADMS's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 61.8%.
Adamas Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: Adamas Pharmaceuticals, Inc.
- Ticker: ADMS
- Exchange: NasdaqGM
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$368.424m
- Shares outstanding: 45.77m
- Website: https://www.adamaspharma.com
Number of Employees
- Adamas Pharmaceuticals, Inc.
- 1900 Powell Street
- Suite 1000
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/25 23:21|
|End of Day Share Price||2021/10/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.